Efficacy of mobile applications to support the care of patients with diabetes mellitus : systematic review and meta-analysis by Bonoto, Bráulio Cezar et al.
Strathprints Institutional Repository
Bonoto, Bráulio Cezar and de Araújo, Vânia Eloisa and Godói, Isabella 
Piassi and Pires Lemos, Livia Lovato and Godman, Brian and Bennie, 
Marion and Diniz, Leonardo Mauricio and Guerra Júnior, Augusto Afonso 
(2016) Efficacy of mobile applications to support the care of patients 
with diabetes mellitus : systematic review and meta-analysis. JMIR 
mHealth and uHealth. ISSN 2291-5222 (In Press) , 
This version is available at http://strathprints.strath.ac.uk/59553/
Strathprints is  designed  to  allow  users  to  access  the  research  output  of  the  University  of 
Strathclyde. Unless otherwise explicitly stated on the manuscript, Copyright © and Moral Rights 
for the papers on this site are retained by the individual authors and/or other copyright owners. 
Please check the manuscript for details of any other licences that may have been applied. You 
may  not  engage  in  further  distribution  of  the  material  for  any  profitmaking  activities  or  any 
commercial gain. You may freely distribute both the url (http://strathprints.strath.ac.uk/) and the 
content of this paper for research or private study, educational, or not-for-profit purposes without 
prior permission or charge. 
Any  correspondence  concerning  this  service  should  be  sent  to  Strathprints  administrator: 
strathprints@strath.ac.uk
Efficacy of mobile applications to support the care of patients with 
diabetes mellitus: a systematic review and meta-analysis of randomized 
controlled trials 
Abstract 
Background- Diabetes Mellitus (DM) is a chronic disease that is considered a 
global public health problem. Education and self-monitoring by diabetic patients 
help to optimize and make possible a satisfactory metabolic control enabling 
improved management and reduced morbidity and mortality. The global growth 
in the use of mobile phones makes them a powerful platform to help provide 
tailored health, delivered conveniently to patients through health applications 
(apps). 
Objective- Evaluate the efficacy of mobile apps through a systematic review and 
meta-analysis to assist diabetes mellitus patients in treatment. 
Methods- We conducted searches in the electronic databases MEDLINE 
(Pubmed), CENTRAL/ Cochrane Register of Controlled Trials and LILACS, 
manual search in references of publications included, systematic reviews, 
specialized journals and gray literature. We considered eligible randomized 
controlled trials (RCTs) conducted after 2008 with participants of all ages, 
diabetes mellitus patients and users of apps to help manage the disease. The 
meta-analysis of glycated hemoglobin (HbA1c) was performed in Review 
Manager Software 5.3. 
Results- The literature search identified 1236 publications. From these, 13 
studies were included that evaluated 1263 patients. In six RCTs, there were a 
statistical significant reduction (P < 0.05) of HbA1c at the end of studies in the 
intervention group. The HbA1c data were evaluated by meta-analysis with the 
following results (MD = - .44; CI: - .59, - .29; P < .10; I² = 32%).The evaluation 
favored the treatment in patients who used apps without significant 
heterogeneity. 
Conclusions - The use of apps by diabetic patients could help improve the 
control of HbA1c. In addition, the apps seem to strengthen the perception of 
self-care contributing better information and health education to patients. 
Patients also become more self-confident to deal with their diabetes, mainly, by 
reducing fear of not knowing how to deal with potential hypoglycemic episodes 
that may occur. 
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Introduction 
Diabetes Mellitus is a chronic disease that is considered a global public health 
problem which results in clinical, social, economic and quality of life impacts for 
patients leading to increased morbidity and mortality [1]. Complications of 
diabetes including cardiovascular diseases are the leading causes of death 
globally, and are responsible for 50-80% of diabetes deaths [2]. In 2014, the 
global prevalence of diabetes was estimated at 9% among adults aged 18yrs 
and older [3]. This is increasing with incidence data demonstrating an overall 
growth in diabetes, particularly among developing countries [4]. There are 
several factors associated with the rising incidence including lifestyle and diet 
changes. There is evidence that a large proportion of cases and complications 
of diabetes may be prevented by changes in lifestyle [5]. Additionally, treatment 
compliance by patients including control of blood pressure, a leading cause of 
death in patients with diabetes, is a major concern across countries [6-10].  
Education and self-monitoring by diabetes patients helps to optimize and make 
possible satisfactory metabolic control enabling improved management and 
reduced morbidity and mortality [11-12]. Self-monitoring of glucose are also 
recommended for patients at risk of developing Type 2 diabetes, characterizing 
it as an important tool for the promotion of health. In the process of encouraging 
patients to improve metabolic control, the importance of self-monitoring of blood 
glucose is one of the main strategies to assist themselves, especially those with 
Type 1 diabetes. This highlights the importance of developing technologies to 
facilitate and optimize self-care, especially in the achievement of therapeutic 
goals for diabetic patients [11-12]. Published studies have already begun to 
discuss the potential of mobile Apps and tablets with improving symptom 
management in patients with chronic diseases [13-16]. 
Global growth in the use of mobile phones makes them a powerful platform to 
help provide tailored health, delivered conveniently to patients. Several studies 
have documented the efficacy, challenges and potential of mobile phones to 
improve health indicators in diabetes [17- 24]. Cell phones are developing 
rapidly mainly with regard to information processing, design and features. 
These devices have evolved from the ability to just make phone calls to multiple 
functions, combining resources on personal computers through software run by 
operating systems, usually called smartphones. This software became known 
as apps. Nowadays, the number of smartphone users is higher than traditional 
mobile phone users. Smartphones allow users to install, configure and access 
specialized apps on their devices. [25] 
Many types of apps have been developed and are available to users on the 
internet such as games, entertainment, productivity, and aspects of health. 
Apps that contribute to the health stand out in this context. In 2015, there were 
an estimated 500 million smartphone¶V users in the world using apps that 
contribute to health care [26]. It is projected there will continue to be a 
significant growth in the use of health apps, e.g. by  2018 it is estimated that 
half of 1.7 billion ³smartphones´ and ³Wablet´ users worldwide will download and 
use health and well-being apps [24, 25]. 
In 2014, the Flurry platform studied app users of the health and well-being 
category from Apple Store [4]. An increase of 62% in the use of these apps was 
seenafter 6 months of follow-up, withthe health and well-being category growing 
87% faster than the apps industry in general. This accelerated growth in apps 
suggests the need to conduct studiesof efficacy, safety and effectiveness to 
assess their benefits on patient care [27]. 
Consequently, given the importance and growth of mobile health apps and the 
potential advantages of this type of technology in addressing major concerns in 
the management of diabetic patients, it is important that the effectiveness of 
these technologies to support patient care need be evaluated. 
Methods 
This principally involved a systematic review and meta-analysis of published 
studies using the Preferred Reporting Items for Systematic Reviews and Meta-
Analysis (PRISMA). [28] 
Eligibility criteria 
The search period considered studies from 2008 to 2016. The rationale for 
adopting this criterion is based on the fact that in 2008, the main app stores 
(iOS, Android), i.e. those that dominate the market, were launched allowing 
users the autonomy to download and use apps in general. Prior to this time, the 
software was only distributed directly by suppliers, manufacturers and the 
number of smartphone users was small. Consequently, the inclusion of studies 
prior to 2008 may introduce bias, characterized by other distribution format and 
use of apps [29]. 
We included RCTs and used the PICOS (participants, interventions, 
comparison, outcomes, study design) to define inclusion criteria.  
Population 
Adults or children were included that were diagnosed with DM type 1 or 2 (with 
or without comorbidities). 
Intervention 
Mobile health apps that users input data, receive feedbacks, connect with 
health professionals or learn about diabetes.  
Control or comparator 
Any comparator was acceptable (traditional control group, an alternative 
intervention, or a within subject pre-post design).  
Outcome measures 
The outcomes considered to evaluate the effectiveness of the apps were: 
biochemical parameters (HbA1c, blood glucose, total cholesterol, weight, High 
Density Lipoprotein Cholesterol (HDL), Low Density Lipoprotein Cholesterol 
(LDL), triglycerides, blood pressure) and quality of life.  
Exclusion criteria 
Studies that just looked solely at the main function of smartphones for 
transmitting health data by Short Message Service (SMS) or by internet as well 
as studies in which health apps had targeted health professionals were 
excluded. Nonrandomized studies, not controlled, quasi-experimental and 
partial results were also excluded. 
Databases and search strategy 
 
The research was performed in the electronic databases MEDLINE (Pubmed), 
CENTRAL / Cochrane Register of Controlled Trials and LILACS (Latin 
American and Caribbean Health Sciences Literature) for published studies 
among 2008 to 2016. A combination of the following MESH terms (Medical 
Subject Headings), "diabetes mellitus type 2", "diabetes mellitus type 1", 
"Mobile Applications", "telemedicine" and their respective entry terms were used 
in the strategy. In addition, a manual search was undertaken of references from 
identified publications and systematic reviews from 2008 for the following 
journals: Online Journal of Public Health Informatics; Journal of Medical Internet 
Research; BMC Public Health; Journal of Telemedicine and Telecare; Journal 
of Diabetes Science and Technology; Journal of Telemedicine and e-Health, 
Health and technology. With the purpose of expanding the coverage of 
publications included a search of the following gray literature sources was 
conducted: Digital Library of Theses and Dissertations of the University of São 
Paulo (USP), Digital Library of Theses and Dissertations of the Federal 
University of Minas Gerais general (UFMG) and electronic database ProQuest 
Dissertation & Theses. No language restriction was applied. 
 
Study selection and data collection 
 
To select studies, references were read in two phases (title/abstract and the full 
article) by two independent reviewers. Disagreements were resolved by a third 
reviewer. 
After full reading of pertinent studies, a standardized form was designed to 
collect data from the selected studies by two independent researchers. The 
form was used to compile information about the duration and period of studies, 
participants at the beginning and end of each study, the age groups, health 
problems and comorbidities. Interventions in both groups of participants, name 
and features of apps, countries where studies were conducted, clinical data and 
other information were also collected. 
Assessment of risk of bias 
 
The evaluation of risk of bias followed recommendations of Cochrane 
Collaboration. Each domain was classified as having a low risk of bias, high or 
unclear. This assessment was performed by two independent researchers and 
disagreements were resolved by consensus [30-31]. 
 Summary of data and statistical analysis 
 
Data collected from HbA1c could be combined in a meta-analysis using random 
effects model from Review Manager Software 5.3. Results were presented as 
average difference (MD) with 95% confidence interval. Heterogeneity analysis 
with an I2> 40% and P value (chi-square test) < .10 were considered as 
significant heterogeneity. Sensitivity analysis was conducted to investigate the 
causes of heterogeneity, excluding one study each time and checking the 
changes in values of I2 and P. Others outcomes were assessed as joint analysis 
because a few studies had provided enough data to be included in a meta-
analysis. A subgroup analysis was also performed to check influence of 
exposure type that participants were submitted to, i.e. conventional or remote 
access to health professionals and the number of features available in the app. 
Results 
Study inclusion 
 
The literature search identified 1236 publications, of which 92 were considered 
potentially eligible. Thirteen studies were finally included in the meta analysis 
[32-41]. The main reasons for the exclusions were the intervention not be apps, 
studies were not RCT and participants not be diabetes patients [Figure 1]. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Flowchart of selection of references to systematic review.  
 
 
Characteristics of studies and participants 
 
The included studies were performed in the United States of America 
[32,33,34], Italy [35,36], England [37], Norway [38], Germany [39], Finland [40], 
Australia [41], Netherlands [42], France [43] and one study was conducted in 
three different countries (Italy, England and Spain) [44]. The duration of studies 
varied from one to 12 months. Eight studies were performed in more than one 
center [32,33,35,37,38,41,43,44], the remainder were performed at a single 
center [34,36,39,40,42]. Only four studies reported conflicts of interest 
[35,36,43,44] [Tab. 1]. 
 
 
 
 
 
 
Table 1. General characteristics of the included studies. 
Study Name (App) Features Country 
Duration 
(months) 
Hsu (2015) 
[34] 
CollaboRhythm 
Storage and feedback of 
glucose data. Graphical 
display of data, stores 
eating habits, physical 
activity. Feedback on 
insulin dose and 
calculating carbohydrate 
consumption, alarms to 
take medicine. 
Telemedicine via SMS 
and videoconferencing. 
 
USA 3 
Drion (2015) 
[42] 
Dbees 
Storage and feedback of 
glucose data, 
carbohydrate intake, 
physical exercise, 
medication. 
 
Netherlan
d 
3 
Quinn 
(2014) [33] 
MDMA 
Storage and educational 
feedback of biochemical 
and physiological data, 
about carbohydrate 
intake and medication. 
 
USA 12  
Holmen 
(2014) [38] 
Few Touch 
Application 
(FTA) 
Storage and feedback of 
glucose data, graphical 
display of data, stores 
eating habits, physical 
activity and planning of 
individual goals. 
 
Norway 12  
Berndt 
(2014) [39] 
Mobil Diab 
(mDiab) 
Storage and feedback of 
glucose data. Generates 
alerts for professionals 
who perform monitoring 
when risk is monitored. 
 
Germany 1 
Nagrebetsk 
(2013) [37] 
t+ Diabetes 
Storage and graphical 
feedback about glucose 
level. Orientation aid in 
self-titration of oral 
hypoglycemic 
medication, under the 
supervision of a nursing 
team. 
 
England 6  
Study Name (App) Features Country 
Duration 
(months) 
Kirwan 
(2013) [41] 
Glucose Buddy 
Storage and feedback of 
glucose data, insulin, 
medication. Graphical 
display of data. Function 
to assist in diet, exercise 
and planning of individual 
goals. 
 
Australia 9  
Rossi 
(2013) [35] 
Diabetes 
InteractiveDiary 
(DID) 
Storage and feedback of 
glucose data. Feedback 
on insulin dose and 
calculating carbohydrate 
consumption, 
telemedicine via SMS. 
 
Italy 6  
Orsama 
(2013) [40] 
Monica 
Feedback on inserted 
biochemical parameters, 
graphical display of data, 
planning individual goals, 
motivational messages 
and change of habits. 
 
Finland 10 
Quinn 
(2011) [32] 
MDMA 
Data storage of 
biochemical, 
physiological, 
carbohydrate intake, 
medication with 
educational feedback. 
  
USA 12  
Castelnuovo 
(2011) [36] 
METADIETA 
Present questionnaires 
about weight and HbA1c, 
data on carbohydrate 
intake, connect via SMS 
with a nutritionist. 
 
Italy 12  
Charpentier 
(2011) [43] 
Diabeo System 
Storage and feedback of 
glucose data. Feedback 
on insulin dose and 
calculating carbohydrate 
consumption. Store 
physical activity. 
 
France 6 
Rossi 
(2010) [44] 
Diabetes 
InteractiveDiary 
(DID) 
Storage and feedback of 
glucose data. Feedback 
on insulin dosage and 
calculating carbohydrate 
intake, telemedicine via 
SMS. 
Italy/ 
England/ 
Spain 
6 
 The main intervention evaluated in the studies was the use of mobile apps to 
assist in the monitoring of diabetes patients. In all studies, the intervention 
group had remote or conventional access to health professionals. Eleven 
different mobile apps were identified as the intervention product. The features of 
apps included health data storage, feedback on physiological parameters, 
motivational messages, function to assist with a healthy diet and exercise, 
functions for insulin dosage adjustment, chat and videoconferencing with health 
professionals, alarm for drug therapy compliance, health goals and calculating 
carbohydrate intake. All participants in the control groups were subjected to 
standardized health treatment [Table 1]. 
Four studies included the percentage of participants that smoked (16 to 17%) 
[32,33,38,40]. Two studies also measured percentage of participants who 
exercise regularly [38,40]. In that studies, 34.4% [38] and 77% [40] of 
participants practice physical activities. The average age of participants of these 
two studies was more than 57 years old. 
The total number of participants who began studies included in this review was 
1263, wherein 1068 participants took part until the end. It was found there was 
no association between sample loss and use of mobile apps or smartphones 
that would compromise outcomes. Regarding ethnicity, only three studies 
reported data. Overall, 50% or more of participants were Caucasian [32,33,37]. 
Education was reported in eight studies. In six studies, 75% or more of the 
participants had, at least, completed high school [32,33,35,42-44] and 60% of 
sample in the intervention group was men [37-40,42]. In one study less than 
50% of the participants had completed high school [38]. Other study reported 
the average years of study among participants, which was 11.7 years [40]. 
One study evaluated if the use of mobile app when compared to standard 
treatment, could present differences in their effectiveness based on the age of 
patients ( 55 or <55 years old). However there were no significant differences 
in the outcomes measured between the two age groups [33]. The baseline 
characteristics of participants are presented in Table 2. 
Table 2.  Baseline characteristics of participants in included studies.  
Study 
Sample 
(N) 
Age in 
years 
(SD) 
Gender  
(% men) 
3DUWLFLSDQW¶V
disease 
'LVHDVH¶V
duration 
(SD) 
 
Hsu (2015) [34] 
   
 
DM type 2 
 
App 20 53.3 -  9.6 
Control 20 53.8 -  9.0 
 
Drion (2015) [42] 
   
 
DM type 1 
 
Study 
Sample 
(N) 
Age in 
years 
(SD) 
Gender  
(% men) 
3DUWLFLSDQW¶V
disease 
'LVHDVH¶V
duration 
(SD) 
App 31 33 (23) 64.5  18 (17) 
Control 32 35 (18) 62.5  15 (14) 
 
Quinn (2014) [33] 
      
 
DM type 2 
  
App (< 55 years) 37 47.3 (6.8) 37.8   6.8 (4.5) 
App ( 55 years) 25 59.0 (2.9) 68.0   10.3 (5.8) 
Control (< 55 
years) 
29 47.4 (7.5) 62.1   8.9 (7.5) 
Control ( 55 
years) 
27 59.5 (2.8) 37.0   9.2 (6.0) 
 
Holmen (2014) [38] 
      
 
DM type 2 
  
App 51 58.6 (11.8) 67.0   11.2 (7.3) 
Appa 50 57.4 (12.1) 50.0   9.6 (8.4) 
Control 50 55.9 (12.2) 40.0   9.4 (5.5) 
 
Berndt (2014) [39] 
      
 
DM type 1 
  
App 34 12.9 (2.0) 62.0   5.0 (3.7) 
Control 34 13.2 (2.9) 56.0   5.3 (4.0) 
 
Nagrebetsk (2013) 
[37] 
      
 
DM type 2  
App 8 56 (8.0) 71.0   3.0 (2.0) 
Control 9 60 (13.0) 71.0   2.3 (7.4) 
 
Kirwan (2013) [41] 
      
 
DM type 1 
  
App 36 
35.97 
(10.67) 
52.7   19.69 (9.64) 
Control 36 
34.42 
(10.26) 
25.0   18.19 (9.77) 
 
Rossi (2013) [35] 
      
 
DM type 1 
  
App 63 38.4 (10.3) 46.0   16.2 (10.0) 
Control 64 34.3 (10.0) 49.1   15 (8.4) 
 
Orsama (2013) [40] 
      
 
DM type 1 
  
App 24 62.3 (6.5) 54.0    - 
Control 24 61.5 (9.1) 54.0    - 
 
Quinn (2011) [32] 
      
 
DM type 2  
App 23 52.8 (8.0) 52.2   7.7 (5.6) 
Appb 22 53.7 (8.2) 45.5   6.8 (4.9) 
Appc 62 52.0 (8.0) 50.0   8.2 (5.3) 
Control 56 53.2 (8.4) 50.0   9.0 (7.0) 
 
Castelnuovo 
(2011) [36] 
      
 
DM type 2/ 
obesity 
  
App 17 49 (16.5) 68.7   -  
Study 
Sample 
(N) 
Age in 
years 
(SD) 
Gender  
(% men) 
3DUWLFLSDQW¶V
disease 
'LVHDVH¶V
duration 
(SD) 
Control 17 54 (11.7) 35.3   - 
 
Charpentier (2011) 
[43] 
   
 
DM type 1 
 
Appd 59 31.6 (12.5) 37.3  14.7 (9.1) 
Appe 60 32.9 (11.7) 38.3  17.6 (8.9) 
Control 61 36.8 (14.1) 34.4  16.9 (10.5) 
 
Rossi (2010) [44] 
      
 
DM type 1 
  
App 67 35.4 (9.5) 44.8   17.1 (10.3) 
Control 63 36.1 (9.4) 41.0   15.8 (10.7) 
Notes: 
N ± number of participants 
SD ± standard deviation 
a- Intervention is the use of the app associated with health counseling of nurses 
specialists in diabetes. 
b- Intervention is the use of the app and data shared with medical researchers 
of the study. 
c- Intervention is the use of the app and data shared with medical researchers of 
the study associated with quarterly reports delivered to participants from data 
entered. 
d- Intervention is the use of the app and access health professionals as control 
group. 
e- Intervention is the use of the app and access health professionals remotely. 
 
Risk of bias 
 
When evaluating risk of bias, 11 out of the 13 studies presented low risk of 
selection bias [32,35-44] and one showed unclear data [34]. However in the 
performance and detection categories, all studies presented high risk of bias. 
Only one study showed unclear data on incomplete outcomes [36]. All studies 
had low risk on selective reporting [Figure 2]. 
 
 
 
 
 
 
Figure 2. Analysis of the risk of bias.   
 
Glycated hemoglobin and hypoglycemic episodes 
 
HbA1c was measured in 12 studies [32-35,37-44]. In six studies, there were 
statistical significance difference in the reduction of this parameter favoring the 
intervention within 12 months of follow-up (P <.03) [32-34,40,41,43]. 
Overall, the meta-analysis showed the effectiveness of the use of apps to 
control diabetes (P< .001), with lower heterogeneity (MD= -.44; CI: -.59, - .29; 
P< .10; I²= 32%). The sensitivity analysis showed that excluding the study [41] 
in the subgroup "Access to usual care" and [35] in the subgroup "Remote 
Access", there was a reduction of heterogeneity in both subgroups to zero 
without changing the direction of outcome [Figure 3]. 
Figure 3. Forest-plot of glycated hemoglobin of diabetes patients who used a 
health app and have access physically or remotelly to health professionals.  
 
 
Hypoglycemic episodes were reported in five studies [34,35,39,43,44]. In one 
study, 30 and 33 mild episodes were recorded in the intervention and control 
groups respectively and a serious episode in the control group [39]. In three 
studies, episodes were recorded in each group without significant diference 
[34,43,44]. In a third study, the intervention group had a lower relative risk (0:14; 
CI 0.07-0.029) of severe hypoglycemic episodes. [35] 
 
 
Subgroup analysis 
 
Subgroup analysis was performed to evaluate if the route of access to health 
professionals for monitoring diabetes, in addition to the app, affected outcomes 
in terms of HbA1c. In seven studies, participants in the intervention group had 
access to health professionals remotely [32-35,37,40], in five studies 
participants had access to usual care [38,39,41,42,44] and one study share 
intervention participants to access health professionals remotely or physically 
[43]. Both subgroups showed favorable results in HbA1c control [Fig. 3]. 
The number of features available in the app of each study was also evaluated to 
check their impact on HbA1c. Four main features were identified in apps that 
contributed to achieving glycemic control. These were "storage and feedback of 
blood glucose data", "function to assist in diets", "function to aid at physical 
exercises practice", "control over dosage and adherence to drug therapy" [45]. 
Subgroups were separated in order to evaluate studies where the apps provide 
one or two features of the four identified for glycemic control (P = .05) 
[37,39,40]. It was demonstrated that the subgroup with fewer features in an app 
had outcomes with borderline significant difference. The subgroup where apps 
had more than two functionalities generated the following results (P <.001) [32-
35, 38,41-44] [Figure 4]. 
Figure 4. Forest plot of glycated hemoglobin of diabetes patients who used a 
health app according to the number of selected app features.  
 
A subgroup analysis was performed to evaluate if there is difference among 
type of diabetes mellitus. Both subgroups showed favourable results of HbA1c 
control to intervention group compared to control group.  
Secondary outcomes 
 
Different secondary outcomes were evaluated in some studies. Four studies 
were conducted using an assessment of fasting blood glucose assessment. 
However, there was no significant reduction in any study [35,39,41,44]. Six 
studies assessed weight changes [35,36,38-40,44]. Four studies assessed 
changes in blood pressure [32,35,40,44] and three studies measured total 
cholesterol, HDL, LDL and triglycerides [32,35,44]. The results are presented by 
a joint analysis [Table 3]. 
Table 3. Joint analysis of secondary outcomes.  
Outcome 
Intervention 
(n) 
Control 
(n) 
Mean Difference 
(95% CI) 
P 
Value 
I² 
(%) 
Fasting blood 
glucose 
[35,39,41,44] 
172 180 0.05 [-1.39, 1.49] 0.95 79% 
 
Body weight 
[35,38,39,44] 
226 193 -0.39 [-1.43, .66] 0.47 0% 
 
Systolic blood 
pressure 
[32,35,40,44] 
221 179 0.10 [-2.36, 2.55] 0.94 0% 
 
Diastolic blood 
pressure 
[32,35,40,44] 
221 179 0.37 [-1.10, 1.85] 0.62 0% 
 
Total cholesterol 
[32,35,44] 
211 169 - 3.44 [-12.87, 6.00] 0.48 44% 
 
HDL [32,35,44] 
211 169 - 2.15 [-5.40, 1.10] 0.19 58% 
 
LDL [32,35,44] 
211 169 1.69 [-5.67, 9.06] 0.65 26% 
 
Triglicerides 
[32,35,44] 
211 169 - 14.67 [-33.40, 4.06] 0.12 58% 
 
Quality of life was assessed in six studies using different measuring 
instruments: Disease-Specific Quality-of-Life (DSQOL) [35], Diabetes Quality of 
Life (DQOL) [41], Diabetes Quality of Life for Youths (DQOLY ) [39], 36-Item 
Short-Form (SF-36) [38,42,44]. Three studies found positive and statistical 
significant changes in quality of life and satisfaction with treatment in the 
intervention group [35,39,44]. Health improvements reported by participants 
with the app were the perception of hyperglycemia episodes, social 
relationships, decreased fear of hypoglycemia, perception that the apps aid 
treatment and healthier dietary habits. 
Discussion 
The meta-analysis found a significant difference throughout 12 months among 
the intervention group in terms of better HbA1c control. However overall there 
were no significant differences with respect to secondary outcomes between the 
groups. These results indicate relevant questions about the potential of tools for 
self-monitoring and self-care by patients and the role of remote access to 
healthcare professionals where there appears to be similar effectiveness with 
conventional access to diabetes patients. 
We believe it is worth mentioning that whilst these results have shown 
significance differences compared to the control group for control of HbA1c, 
only two studies [37,40] reached values considered suitable for glycemic 
control, which is 7%, according to the global consensus [46,47]. This 
demonstrates the major challenge in achieving satisfactory results in the 
treatment of diabetes, despite all groups of participants having shown better 
average results at end of the studies. 
In other studies that averaged more than 7%, the maximum average value 
found was 8.63% in the intervention group [43]. The United Kingdom 
Prospective Diabetes Study shows that every percentage point decrease in 
HbA1c reduces by 35% the risk of vascular complications [48]. Another study 
showed that HbA1c values between 7.4 ± 1.4 and 7.7 ± 1.4 do not increase the 
risk for retinopathy and nephropathy, respectively, while values above 9.3 ± 1.1 
and 9.6 ± 1.2 show increased risk of development and progression of 
retinopathy and nephropathy, respectively [49]. 
Association between use of apps and remote access to health professionals 
demonstrated great effectiveness in controlling HbA1c. Studies in which 
intervention groups accessed health professionals similar to the control groups 
also showed significance difference in outcomes. This suggests that the use of 
apps by themselves may not be more effective than standard treatment. Apps 
have better results when they include tools of remote communication with 
health professionals or access them face-to-face. 
The number of features that apps offer also appear to influence HbA1c levels. 
Studies in which apps had even two features showed borderline results 
between the two groups. Results were favorable when more than two features 
of control were available in the app, i.e. more than two of "storage and feedback 
of blood glucose data," "function to assist in diets," "function to aid at physical 
exercises practice", or "control over dosage and adherence to drug therapy ". 
Studies evaluating quality of life reported that use of apps have increased the 
perception of knowledge by participants about their health problems. This may 
represent a contribution to perceived need for self-care by users [35,39,44]. 
These results corroborate the proposed measures of health promotion by the 
International Diabetes Federation [12]. 
The high risk of bias for blinding participants and masking interventions is 
followed by almost the impossibility of health professionals and patients 
unaware of the use of apps and smartphones in care process. However, some 
studies reported there is no empirical evidence to support the conclusion that 
problems in masking the interventions may compromise the results [50,51]. 
An important characteristic measured in these studies ZDV SDUWLFLSDQWV¶
education. It is expected that individuals with higher education have greater 
ability in adopting new technologies. This may be a limitation of the studies 
because results favouring apps users might not have had the same outcomes if 
participants had less education. In a study conducted in Norway [38], most of 
the participants had education below high school, any measured outcomes 
showed results with significance difference for one of groups. However, the 
Norwegian study may not be a good reference because as the Nordic countries 
are highly digitalized societies, which is not yet a reality in a number of countries 
including Brazil [52]. 
All studies included in this systematic review were undertaken in developed 
countries and therefore it is necessary to measure ability to generalizability to 
developing countries. Access to apps requires the presence of a smartphone or 
tablet and internet access for satisfactory performance. In Brazil, statistics from 
portal Statista presents suggests that by 2017,42.5% of mobile users will be 
smartphone users [53]. In absolute numbers, Brazil will have nearly 170 million 
mobile phone users by 2018 [54], suggesting that more than one third of 
Brazilians will have access to a smartphone by 2018. According to the World 
Bank, internet access in Brazil in 2014 reached 57.6% of the population [55], 
allowing the potential use of apps in health care processes. 
Age may also be an influencing factor to the adoption of new technologies [56-
60]. In five of the studies, participants had an average age under 40 years 
[35,41-44]. In other studies, participants had a mean age of 50 years, except 
one study with teenagers. Studies with participants with an average age of 40 
years showed improvements in outcomes including HbA1c [41,43], triglycerides 
[44] and a relative risk reduction shield for hypoglycemic episodes[35]. 
However, one study showed no significant difference in outcomes among 
people under and over 55 years old in the two groups [34]. 
A last important analysis is related to a higher proportion of men (60% of 
sample) in the intervention group of some studies [37-40, 42]. Reference 
showed that men are more interested in adopting new technologies, while 
women prefer to take opinions before use [61]. However, the included studies in 
this review showed men and women had comparable results. 
After performing the analysis, it can be concluded that use of apps for diabetes 
control as an aid to treatment can be considered an effective measure, 
especially when patients have access to health professionals. Sustainable 
health systems need to invest in disease prevention and health promotion 
actions. Self-monitoring actions aim to raise awareness and education about 
the role of patients and family in managing their health problems. At the same 
time, smartphones with internet access have the potential to provide data from 
clinical parameters measured at home that can relieve pressures on health 
systems directly due to improved access for those who really need to use clinics 
and hospitals and, indirectly, by reducing costs and increasing therapeutic 
effectiveness. 
The results from this meta analysis suggest that self-monitoring can be 
delivered by smartphones, with increasing use of smartphones by people from 
different socioeconomic conditions. The use of such devices can still be 
considered complex and potentially currently a barrier to access among elderly 
patients. However in the medium term, population aging will include almost all in 
a highly connected and digitalized society. 
Conclusion 
 
This systematic review suggests that use of apps in patients with diabetes could 
help improve the control of HbA1c. In addition, the apps seem to strengthen the 
perception of self-care contributing better information and health education to 
diabetes patients. App features including "storage and feedback of blood 
glucose data", "assist in diet", "help practice in physical exercise", and "assist in 
control of dosage and adherence to drug therapy" as well as access to health 
care professionals contributes to a better glycemic control. Patients also 
become more self-confident to deal with their diabetes, mainly, by reducing fear 
of not knowing how to deal with potential hypoglycemic episodes that may occur 
and improving their quality of life. 
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